Beacon Oncolytic Viruses

Track the clinical trial and drug development landscape for Oncolytic Viruses

What we cover

Beacon Oncolytic Viruses is a manually curated database solution that includes all publicly available data for preclinical, active, approved, and discontinued virus-based therapies being developed for oncology indications. The database covers:

  • Genetically modified or naturally occurring oncolytic virus-based therapies
  • Virus based therapeutics including therapeutic viral-vaccines

New data expansionDeals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.

How Beacon helps

Here are a few example use cases that have benefitted our clients in accelerating their Oncolytic Viruses development programs:

  • Benchmark drug development and clinical trial strategies against competitors.
  • Getting an in-depth competitive landscape overview of the competitors and their assets in the clinic.
  • Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on progression in the clinicvirus based therapies, and much more.
  • Identify new players and new assets in entering the clinic and monitor their progress.

How Beacon Oncolytic Viruses works

Search the clinical trial and drug landscape by virus type and family, genome types, transgenes, genes deleted or modified for pathway or signalling alteration, envelope modifications, or promoter related modifications, routes of administration, diseases, biomarkers, line of therapy, instantaneously and/or extract the data points you need to conduct more complex analyses.

Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the oncolytic viruses space.

How we target the data for oncolytic viruses

We house all publicly available sources of data updated with 24 – 48 hours of publication proactively.  Our sources cover (but are not limited to):

  • Clinical trials registries
  • Scientific journals and publications
  • Company reports and presentations
  • Press releases
  • Conference reports and abstracts
  • Government and regulatory organizations
  • Newspapers and other media
  • Patents

Related content

2023 Oncolytic Viruses Landscape Review

Find out more

Infographic 2023 Oncolytic Viruses ESMO Abstracts Analysis

Find out more

SITC 2023 Oncolytic Viruses Annual Meeting Abstracts

Find out more

What our customers say

Beacon is a great database that people should pay attention to. It's much better than many of the more generic databases that try to capture all data about everything

Top Biotech Company

Our Oncolytic Viruses Expert

Longli Zhou is the lead research analyst for Oncolytic Viruses in the Beacon team.

Sign up for our bi-weekly newsletter with the latest Oncolytic Viruses landscape with data from Beacon Oncolytic Viruses.

Subscribe to newsletter

Other Beacon Solutions

Cell Therapy
Cancer Vaccine
Gene Therapy
Immune Tolerance
Beacon ADC Logo


Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more

Find out more


Covering all genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications.

Find out more

Beacon Bispecific Logo


Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more

Find out more

Cancer Vaccine Logo 2021


Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.

Find out more

Beacon Checkpoint Logo


Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets

Find out more


Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.

Find out more

Beacon DDR Logo


Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.

Find out more

Beacon Gene Therapy Logo


From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.

Find out more


Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.

Find out more


Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.

Find out more


Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.

Find out more

Beacon TPD Logo


Beacon TPD provides the solution you need to master the targeted protein degradation field.

Find out more

Any questions? Contact us

To learn more about how we can tailor Beacon Oncolytic Viruses to help you, get in touch with our sales team


Nattasha Sidhu

Oncolytic Viruses Account Manager

Contact the Team

About Beacon

We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.